DIRS.INFO The most relevant business & tech news

☆ Trump's lawyers are hunting for the identities of secret consultants who approved Russiagate Pulitzer Prizes
▼ + stars: | 2024-03-07 | by ( Jacob Shamsian | ) www.businessinsider.com time to read: +15 min

AdvertisementIn an overlooked lawsuit, Donald Trump's lawyers are exhibiting a habit from his White House days: Hunting for anonymous sources. At each turn, a lawyer for the Pulitzer Board members stopped their clients from answering. The journalists whom Trump's lawyers deposed did, however, offer some characterization of the "consultants" who conducted the reviews. The Pulitzer Prize Board is hosted by Columbia University, in Manhattan, which manages the small organization's payroll and offers institutional support. Chad Bowman, a Ballard Spahr attorney representing the Pulitzer board members, directed Business Insider to court filings.

Persons: Donald Trump, —, Donald Trump's, Trump, Pulitzer, Robert Mueller, Quincy Bird, Katherine Boo, Boo, Chad R, Bowman, Ballard Spahr, don't, Marjorie Miller, Miller, Weber, Crabb, Wein, Neil Brown, David Remnick, Nicole Carroll, Lee Bollinger, Kevin Merida, Viet Thanh Nguyen, Lee C, Bollinger, David Ake Trump's, Gail Collins, John Daniszewski, Bird, Daniszewski, Dana Canady, doesn't, Bebeto Matthews, Collins, we've, John Durham, Hillary Clinton, James Comey, Brown, Chad Bowman, Ballard, Evan Vucci Trump, Christopher Steele, Jeff Gerth's, Gerth, You've Organizations: Service, Business, The New York Times, Washington Post, American, The Washington Post, Pulitzer, Times, Post, PAC Trump, Columbia University, Mar, Poynter Institute for Media Studies, Tampa Bay Times, New Yorker, Los Angeles Times, Associated Press, Global Enterprise, New, AP, Katherine Boo , New York Times, Trump, Republican, Columbia Locations: Russia, Chad, Manhattan, Florida, USA, New York City, Mar, Katherine Boo ,, New York, Palm Beach , Florida, United States, Washington, DC

☆ Pfizer RSV vaccine maintains protection in older adults over two seasons in trial
▼ + stars: | 2024-02-29 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Pfizer 's vaccine against respiratory syncytial virus maintained protection for older adults across two full seasons of the disease in an ongoing late-stage clinical trial, the company announced Thursday. The shot's efficacy declined slightly compared with the levels of protection after one RSV season, but the new data suggests that the jab generally offers durable protection for adults ages 60 and above, who are more vulnerable to severe illness from RSV. The jab showed 66.7% efficacy against that condition after one RSV season. Pfizer noted that the vaccine showed consistent efficacy against RSV A and RSV B, which are the two major subtypes of the virus, after the second RSV season. Analysts don't expect the committee to make a final recommendation until June – a decision that may have huge implications for Moderna , which is hoping to launch its own RSV jab this year.

Persons: – Organizations: Pfizer, GlaxoSmithKline, Centers for Disease Control, Moderna Locations: Northern, Southern

☆ Gen Z like 'safety capitalism.' It's a lot like what we have now but with more help for people who lose their jobs or get sick.
▼ + stars: | 2024-02-28 | by ( Jacob Zinkula | ) www.businessinsider.com time to read: +5 min

Gen Zers are less likely to take certain risks, which could be one reason they want more of a social safety net. If you ask many Gen Zers that question, they'll say the current social safety net is insufficient. AdvertisementSixty-five percent of Gen Zers think the government should provide a job to anyone who wants one, according to a Wake Forest survey of 2,000 Gen Zers and millennials conducted with YouGov in 2022. Exactly what, if any, changes the US should make to its social safety net is up for debate. Some young people may look to Europe, where countries generally have a larger social safety net than the US.

Persons: —, Zers, Christina Elson, Elson, millennials, Gen Zers, Gen, Z, it's, Charlie Munger, Munger Organizations: Service, Center, Wake Forest University, Wake, YouGov, Social Security Locations: American, Europe, Germany

☆ Viking stock doubled Tuesday. Here's where the next moves in the obesity space could come from
▼ + stars: | 2024-02-27 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +8 min

VKTX YTD mountain Viking shares year to date Then, Viking shares more than doubled in trading on Tuesday, putting the stock on pace to report a more than 300% year-to-date gain, after the company said its GLP-1/GIP receptor agonist VK2735 hit all its primary goals in a phase 2 clinical trial. The Tema Cardiovascular and Metabolic ETF (HRTS) , which is up 12% year to date, owns Novo, Lilly and Viking. Still early days Some analysts and investors admit it is still very early days for obesity treatment and many questions remain to be answered. "We continue to expect above consensus growth in the space, as we are bullish on adoption from payers and broader obesity uptake," Meacham wrote. For obesity only, Lilly has already gained a 38% share, despite only being in the market for 13 weeks, he said.

Persons: Eli Lilly, Geoff Meacham, Meacham, Lilly, Yuri Khodjamirian, Khodjamirian, Jeff Jonas, Becton Dickinson, Novo, BofA's Meacham, What's, Tema's, it's, Gabelli's Jonas, he's, William Blair, Andy Hsieh, Hsieh Organizations: Novo Nordisk, Bank of America, Centers for Disease Control, Zealand Pharma, Viking Therapeutics, Zealand, Food and Drug Administration, Novo, Metabolic, Therapeutics, Pharmaceuticals, Rock, AstraZeneca, Roche, Gabelli Funds, FDA, Viking, Merck, Pfizer Locations: U.S, Tema, Novo Nordisk's, GLP, Lilly

☆ Whirlpool CEO: Critical company milestone as we close European transactions and transform portfolio
▼ + stars: | 2024-02-26 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWhirlpool CEO: Critical company milestone as we close European transactions and transform portfolioMarc Bitzer, Whirlpool CEO, joins 'Money Movers' to discuss Bitzer's upcoming message to investors, Whirlpool's plans to modify its business in Europe, and more.

Persons: Marc Bitzer Organizations: Whirlpool Locations: Europe

☆ Here are Friday's biggest analyst calls: Rivian, DraftKings, Nio, Fox, Carvana, Pfizer and more
▼ + stars: | 2024-02-23 | by ( Alex Harring | ) www.cnbc.com time to read: +9 min

Here are Friday's biggest calls on Wall Street: UBS double-downgrades Rivian The firm said to sell the electric vehicle maker's stock, joining a growing group of concerned analysts following the company's earnings report. Raymond James upgrades Carvana The investment bank moved Carvana to market perform from underperform following the fourth-quarter earnings results. Guggenheim initiates Pfizer The firm opened coverage of the biopharmaceutical stock with a buy rating and $36 price target. " Rosenblatt initiates Adeia The firm began coverage with a buy rating and $15 price target. Roth MKM initiates CPI Card Group Roth MKM started coverage of the financial technology stock with a buy rating and $40 price target.

Persons: Ross, ROST, Raymond James, EBITDA, 4Q23, Guggenheim, ATNI, Morgan Stanley, Brighthouse, Rosenblatt, Roth MKM, Fred Imbert Organizations: UBS, Barclays, CNBC, Citi, Fox, JV, Ross, Price, Pfizer, DRG, Equitable, JPMorgan, Traction, JPMorgan downgrades Locations: 1Q24, Xperi, 4Q22

☆ Pfizer's expectations have been rightsized, has potential for $5 EPS: Cantor Fitzgerald's Chen
▼ + stars: | 2024-02-22 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailPfizer's expectations have been rightsized, has potential for $5 EPS: Cantor Fitzgerald's ChenLouise Chen, Cantor Fitzgerald, and Michael Yee, Jefferies, joins 'Power Lunch' to discuss Chen's bull case for Pfizer, Yee's bull case for Moderna, and more.

Persons: Fitzgerald's Chen Louise Chen, Cantor Fitzgerald, Michael Yee, Jefferies Organizations: Pfizer, Moderna

☆ Gen Z prefers paychecks over promotions, survey says
▼ + stars: | 2024-02-06 | by ( Allie Kelly | ) www.businessinsider.com time to read: +4 min

Advertisement"Since 2021, Gen Z has been living with rates of inflation not seen in the US in decades," the Standard reported. AdvertisementAccess to loans, a strong 401(k) retirement account, and reliable insurance coverage are benefits that Gen Zers expect from employers. Over 90% of Gen Zers and millennials said they're considering leaving their jobs, per a 2023 LinkedIn survey. AdvertisementBy offering intentional tools toward sustained economic stability, The Standard said companies will have better luck recruiting and retaining Gen Z workers. Are you a Gen Z worker and willing to share details about your economic stability goals and how you plan to achieve them?

Persons: —, Zers, Gen Z, Gen Zers, X, millennials Organizations: Service, Business, Bureau of Labor Statistics, Standard Locations: homebuying

☆ I'm a gig worker who argued for Seattle's new minimum pay laws. Now, I'm fighting for my Instacart job.
▼ + stars: | 2024-02-03 | by ( Alex Bitter | ) www.businessinsider.com time to read: +5 min

This as-told-to essay is based on a conversation with Michelle Balzer, an Instacart driver in Seattle. Balzer was among those who advocated for PayUp, a series of bills meant to protect gig workers passed by Seattle's city council. One of the laws, which requires companies like Instacart to pay contractors the equivalent of the city's $19.97-an-hour minimum wage, took effect on January 13. An Instacart spokesperson told BI: "Due to new regulations imposed by the Seattle City Council, we're making several changes to how Instacart operates in Seattle. AdvertisementDo you work for Instacart, DoorDash, Walmart Spark, or another gig work app and have a story idea to share?

Persons: Michelle Balzer, Balzer, I've, Instacart, PayUp, It's Organizations: Service, PayUp, Business, Shoppers, Seattle, Seattle City Council, Safety, Walmart Locations: Seattle, Seattle's, Pacific Northwest, PayUp, Instacart, Washington, DoorDash

☆ US Government Sends Initial Offers for Medicare Drug Price Cuts
▼ + stars: | 2024-02-01 | by ( Feb. | At A.M. | ) www.usnews.com time to read: +1 min

(Reuters) - The Biden administration is sending drugmakers opening offers for the U.S. Medicare program's first ever price negotiations on Thursday, the White House said in a statement. President Joe Biden's signature Inflation Reduction Act (IRA) allows Medicare, which covers 66 million Americans mostly aged 65 and older, to negotiate prices for some of its most costly drugs. The initial offers have been sent to manufacturers of 10 high-cost medicines, which include Bristol Myers Squibb and Pfizer's blood thinner Eliquis, Merck & Co's diabetes drug Januvia and Johnson & Johnson's blood thinner Xarelto. The HHS and White House did not disclose details on the offers. (Reporting by Urvi Dugar and Sriparna Roy in Bengaluru; Editing by Toby Chopra and Sriraj Kalluvila)

Persons: Biden, Medicare program's, Joe Biden's, Januvia, Johnson, Urvi Dugar, Sriparna Roy, Toby Chopra, Sriraj Organizations: Reuters, U.S, Medicare, U.S . Department of Health, Human Services, Bristol Myers Squibb, Merck, HHS, White Locations: Bengaluru

☆ GSK posts blowout RSV vaccine sales, raises outlook as shots give big pharma a boost
▼ + stars: | 2024-01-31 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

GlaxoSmithKline on Wednesday lifted its long-term outlook following the smash-hit launch of its new RSV vaccine. GSK in November had forecast 2023 sales for the shot Arexvy between £900 million, or $1.1 billion, and £1 billion, or $1.26 billion, following its strong launch in the U.S. The company's RSV shot in part drove the higher forecast. The vaccine has about 70% market share for RSV, Walmsley added on Wednesday. Meanwhile, biotech company Moderna hopes to launch its own RSV vaccine this year.

Persons: Emma Walmsley, Walmsley, Arexvy, That's, Pfizer's, Albert Bourla, Bourla Organizations: GlaxoSmithKline, Stevenage, GSK, U.S, Pfizer, U.S . Food, Drug Administration, Moderna Locations: Britain, British, U.S, Canada, Japan

☆ BofA's Geoff Meacham on Pfizer earnings: The story is still about Covid contraction
▼ + stars: | 2024-01-30 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailBofA's Geoff Meacham on Pfizer earnings: The story is still about Covid contractionGeoff Meacham, Bank of America Securities senior pharmaceuticals analyst, joins 'Squawk Box' to break down Pfizer's quarterly earnings results, Big Pharma 2024 outlook, and more.

Persons: Geoff Meacham Organizations: Pfizer, Bank of America Securities, Big Pharma

☆ Pfizer beats earnings estimates as declining Covid business loses less revenue than expected
▼ + stars: | 2024-01-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Pfizer on Tuesday posted a surprise adjusted fourth-quarter profit, as the company's declining Covid business performed better than expected. The company reversed roughly $3.5 billion in revenue related to the expected return of 6.5 million doses of its Covid drug, Paxlovid, from the U.S. government. That hit is less than the $4.2 billion Pfizer initially expected for the return of nearly 8 million doses of Paxlovid. Pfizer's Covid vaccine raked in $5.36 billion in revenue for the quarter, down 53% from the same period last year. For the fourth quarter, Pfizer booked a net loss of $3.37 billion, or 60 cents per share.

Persons: Paxlovid, That's Organizations: Pfizer, U.S ., Analysts, LSEG Locations: U.S

☆ Nike's Sue Bird documentary is heading to Netflix and it's another coup for brand-funded films
▼ + stars: | 2024-01-29 | by ( Lucia Moses | ) www.businessinsider.com time to read: +3 min

"Sue Bird: In the Clutch," a documentary on the career and personal life of the WNBA star, wasn't the most buzzed-about film at Sundance. Nike's success could encourage more brands to follow its leadNike has long been a big player in brand-funded films. Many brands dream of getting their films on Netflix, where even relatively small viewership numbers are bigger than they'd get on a rival streamer. Brands often work alongside traditional Hollywood players, which lends credibility to film projects. But the more films like "In the Clutch" get wide distribution, the more other brands could be encouraged to pursue similar storytelling.

Persons: Sue Bird, Werner Herzog, Sarah Dowland, RogerEbert.com, IndieWire, it's, Beckham, Justin Biskin —, Ron Howard, Brian Grazer's, Oscar, Alex Gibney's Jigsaw, Jay Ellis's Organizations: WNBA, Sundance, Entertainment, Business, Netflix, Nike, Iron Entertainment, Apple, HBO, Procter, Gamble, Marriott, Hollywood Locations: Canada, Hollywood

It was down only 14% from the previous weekend and brings its running domestic total to $42.3 million. Political Cartoons View All 253 ImagesThis was the first moviegoing weekend following Oscar nominations. Searchlight’s “Poor Things,” nominated for 11 Oscars, including best picture, best director and best actress for Emma Stone, got a 43% boost from last weekend with an estimated $3 million. And A24’s “The Zone of Interest,” which had five nominations, including best picture and best director for Jonathan Glazer, expanded to 317 screens, where it earned $1.1 million. Universal had leading Oscar nominee “Oppenheimer” in 1,262 theaters, where it earned an additional million dollars this weekend.

Persons: holdovers, “, Jason Statham actioner, It's, “ Oppenheimer, ” “ Barbie, ”, Jeffrey Wright, Emma Stone, Jonathan Glazer, Alexander Payne's “, Glazer's, Jonathan Organizations: American, Amazon MGM Studios, Warner Bros, Universal Locations: North America

☆ Slack's Christina Janzer is counting on AI to help workers use their time more effectively in 2024
▼ + stars: | 2023-12-29 | by ( Josée Rose | ) www.businessinsider.com time to read: +6 min

While I don't think AI is going to solve everything, I'm really excited for the role that AI is going to play in making work better. AI is really going to help people balance their workday. I think that's really going to help people clear their day and stop spending so much time on those more routine tasks that could just be automated. I think it's also going to give us an opportunity to think about productivity in a much more meaningful way. You have to really think about how you're structuring your day in order to maximize productivity.

Persons: Christina Janzer, she's, —, Salesforce, Slack, We're, I'm, it's, they're Organizations: Service Locations: Business, America

☆ Why we see a way forward for Nvidia in China — plus our take on 2 other stocks in the news
▼ + stars: | 2023-12-13 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +8 min

Meanwhile, Jim Cramer's interview with an influential member of President Joe Biden's cabinet proved encouraging for Club holding Nvidia . It's been a two-session roller-coaster ride that illustrates the importance of staying disciplined and not chasing stocks while they're surging for non-fundamental reasons. Traders were trying to front-run the official announcement, pushing Linde stock up 4.53% Tuesday, to an all-time high of $426.72 per share. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Nvidia CEO Jen-Hsun Huang at the Consumer Elctronics Show (CES) in Las Vegas, USA, 04 January 2017.

Persons: Linde, Jim Cramer's, Joe Biden's, It's, Pfizer's, drugmaker Seagen, there's, Gina Raimondo, Jim, Biden, Raimondo, " Raimondo, Cigna, Humana's, —, Humana, Aetna's, Jim Cramer, Jen, Hsun Huang, Huang, Andrej Sokolow Organizations: Club, Nvidia, LIN, Linde, Nasdaq, Traders, . Commerce, U.S, Bank of America, Wall Street Journal, Humana, CNBC, Consumer, Audi, Getty Locations: China, U.S, Wall, Las Vegas, USA

☆ Blackstone explores sale of Anthos Therapeutics -sources
▼ + stars: | 2023-12-04 | by ( David Carnevali | ) www.reuters.com time to read: +2 min

Signage is seen outside the Blackstone Group headquarters in New York City, U.S., January 18, 2023. Anthos, which does not generate any revenue because its products have not yet hit the market, could be worth several billion dollars in a potential sale, significantly more than the $250 million that Blackstone invested when it founded Anthos in 2019, the sources said. The company's anticoagulants have made significant progress in late-stage clinical trials, the sources added. Blackstone is working with investment bankers to explore a sale of Anthos, the sources said, cautioning that no deal is certain and requesting anonymity because the matter is confidential. Anthos has licensed from Novartis an antibody used in the development of its blood thinners and granted it a minority stake.

Persons: Blackstone, Anthos, Bayer, Eliquis, David Carnevali, Leslie Adler Organizations: Blackstone Group, REUTERS, Blackstone Inc, Anthos Therapeutics, Novartis AG, Novartis, Myers Squibb, Alnylam Pharmaceuticals, Thomson Locations: New York City, U.S, Cambridge , Massachusetts, Anthos, Bristol, German, New York

☆ Pfizer's twice-daily weight loss pill joins a long list of obesity drug flops
▼ + stars: | 2023-12-02 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

That includes Novo Nordisk 's Wegovy and diabetes treatment Ozempic as well as Eli Lilly 's diabetes drug Mounjaro. They have all skyrocketed in popularity — and slipped into shortages — over the last year for safely and successfully causing significant weight loss. But before the current weight loss industry gold rush, the path to treating obesity was strewn with failures dating back decades. In its full-year 2019 earnings, Eisai reported that Lorcaserin had sales of $28.1 million in the U.S. for the year. Sanofi's rimonabantAn obesity drug called rimonabant from Sanofi and Aventis was withdrawn from all markets in 2008 due to the risk of serious psychiatric problems, including suicide.

Persons: Eli Lilly, drugmakers, lorcaserin, Eisai, Lorcaserin Organizations: Getty, Pfizer, Novo Nordisk, U.S, Drug Administration, FDA, Aventis, Abbott Laboratories Locations: U.S, Sanofi

☆ Pfizer drops plan to study twice-daily obesity pill in late-stage studies
▼ + stars: | 2023-12-01 | by ( ) www.reuters.com time to read: +2 min

A person walks past the Pfizer Headquarters building in the Manhattan borough of New York City, New York, U.S., November 9, 2020. Pfizer said it would instead focus on a once-daily, modified release version of danuglipron and "gathering the data to understand its potential profile". In the current study of the twice-daily version, Pfizer said the drug, however, met the main goal of reducing weight in adults with obesity and without type 2 diabetes. Pfizer said while the common side effects in the twice-daily version study were mild, it saw high rates of those events in the trial. However, no new safety signals were observed in the study, Pfizer said.

Persons: Carlo Allegri, danuglipron, Eli Lilly's, Mikael Dolsten, Pfizer, Manas Mishra, Michael Erman, Shinjini Organizations: Pfizer, REUTERS, Zepbound, Thomson Locations: Manhattan, New York City , New York, U.S, Bengaluru, New York

☆ Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
▼ + stars: | 2023-12-01 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Pfizer on Friday said it would stop developing the twice-daily version of its experimental weight loss pill after obese patients taking the drug lost weight but had trouble tolerating the drug in a mid-stage clinical study. The company is betting on a successful weight loss pill to help it rebound from plummeting demand for its Covid products and a roughly 40% share price drop this year. Pfizer's phase two trial on its twice-daily pill followed around 600 obese adults who did not have Type 2 diabetes. Meanwhile, placebo-adjusted weight loss was 8% to 13% at 32 weeks and 5% to 9.5% at 26 weeks, Pfizer said. No new safety issues were observed, and danuglipron was not associated with increased liver enzymes like Pfizer's other discontinued weight loss pill.

Persons: Albert Bourla, Eli Lilly, danuglipron Organizations: Pfizer, Novo Nordisk, Nordisk's Wegovy

☆ Goldman says buy beer powerhouse Constellation. One of its reasons made us think
▼ + stars: | 2023-12-01 | by ( Paulina Likos | ) www.cnbc.com time to read: +4 min

Goldman Sachs believes Constellation Brands (STZ) has the potential to revive sales in its struggling Wine & Spirits division. It's not impossible, but we're more bullish on the company's core beer business. In the Goldman note, Herzog acknowledged that Wine & Spirits has, indeed, struggled. Management's emphasis on "driving shareholder returns reduces the risk of its underperforming Wine business," she added. We had been hoping to hear news about a breakup of its underperforming Wine & Spirits, which did not happen.

Persons: Goldman Sachs, It's, Bonnie Herzog, Goldman, Herzog, Jim Cramer, Jim Cramer's, Jim, Luke Sharrett Organizations: Constellation Brands, Modelo, Wine, Constellation, CNBC, Workers, LLC, Bloomberg, Getty Locations: Corona, Pacifico, Simi, U.S, Louisville , Kentucky

☆ We're updating price targets for 6 stocks and changing our rating for Palo Alto
▼ + stars: | 2023-12-01 | by ( Jeff Marks | ) www.cnbc.com time to read: +7 min

The Club on Friday is changing the rating and price target on one of our favorite stocks, and updating the price targets on 5 other names in the portfolio to reflect recent quarterly earnings reports, new developments at the companies and broader economic forces. We're increasing our price target on shares of Palo Alto (PANW) to $300 from $280. We're raising our price target on shares of Salesforce (CRM) to $275 from $240. We're lowering our price target for Ford (F) stock to $13 from $16. We're lifting our price target on shares of Eli Lilly (LLY) to $630 from $600.

Persons: PANW, Ford, Linde's, Linde, Eli Lilly, it's, It's, Jim Cramer's, Jim Cramer, Jim Organizations: Palo, Palo Alto Networks, Costco, Ford, UAW, Management, Motors, GM, Linde, LIN, P Healthcare, donanemab, Novo Nordisk, Pfizer, CNBC Locations: Alzheimer's, Lilly, Santa Clara , California

☆ Why Pfizer's latest stumble in the obesity market is a boon for Eli Lilly
▼ + stars: | 2023-12-01 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +5 min

In June, the New York-based pharmaceutical giant stopped developing a different obesity pill, known as lotiglipron , due to concerns about liver safety. Meanwhile, Eli Lilly shares were mainly flat in afternoon trading, at around $591apiece. We lifted our Eli Lilly price target Friday to $630 per share, up from $600. Eli Lilly and Danish rival Novo Nordisk (NVO) are the two dominant players in the obesity market. The longer it takes for competitors to get to this burgeoning market, the more revenue first-movers Eli Lilly and Novo Nordisk can capture.

Persons: Eli Lilly, Jim Cramer, Lilly's, Novo's, Jim, Eli Lilly —, —, Eli, that's, — Novo's, Novo, semaglutide, Jim Cramer's, AJ Mast Organizations: Pfizer, Club, Novo Nordisk, Pharmaceutical, Amgen, AstraZeneca, Bank of America, U.S . National Library of Medicine, U.S . Food, Drug Administration, CNBC, Bloomberg, Getty Locations: New York, Danish, Lilly, U.S, Indianapolis , Indiana

☆ Cramer's Lightning Round: 'I'm not a buyer' of NIO
▼ + stars: | 2023-11-30 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

Stock Chart Icon Stock chart icon Iron Mountain's year-to-date stock performance. Stock Chart Icon Stock chart icon Q2's year-to-date stock performance. Stock Chart Icon Stock chart icon Pfizer's year-to-date stock performance. Stock Chart Icon Stock chart icon NIO's year-to-date stock performance. Stock Chart Icon Stock chart icon Cava's year-to-date stock performance.

Persons: I've, let's Organizations: Uranium Energy, Uranium Energy Corp, Pfizer, American Airlines, NextEra Energy Partners

Search resuls for: "Zer's"

25 mentions found